Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome

R. Fogari, A. Zoppi, A. Mugellini, P. Lazzari, G. Derosa

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The aim of this study was to compare the effect of aliskiren and losartan on fibrinolysis and insulin sensitivity (IS) in hypertensive patients with metabolic syndrome. After 2-week placebo period, 76 outpatients with mild to moderate hypertension and metabolic syndrome were randomized to aliskiren 300mg od or losartan 100mg od for 12 weeks. Clinic blood pressure (BP), plasma PAI-1 antigen, and tPA activity were evaluated after 2, 4, 8, and 12 weeks of treatment. At the end of each treatment period patients performed an euglycemic hyperinsulinemic clamp and IS was assessed by glucose infusion rate (GIR). Both aliskiren and losartan induced a significant and similar SBP/DBP reduction (-15.6/10.7mmHg and -15.5/10.5mmHg, p

Original languageEnglish
Pages (from-to)892-896
Number of pages5
JournalHormone and Metabolic Research
Volume42
Issue number12
DOIs
Publication statusPublished - 2010

Fingerprint

Losartan
Fibrinolysis
Insulin Resistance
Insulin
Patient treatment
Glucose Clamp Technique
Plasminogen Activator Inhibitor 1
Blood pressure
Clamping devices
Outpatients
Placebos
Blood Pressure
Hypertension
Plasmas
Antigens
Glucose
Therapeutics
aliskiren

Keywords

  • AT1R blockers
  • PAI-1 antigen
  • renin inhibition
  • tPA activity

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome. / Fogari, R.; Zoppi, A.; Mugellini, A.; Lazzari, P.; Derosa, G.

In: Hormone and Metabolic Research, Vol. 42, No. 12, 2010, p. 892-896.

Research output: Contribution to journalArticle

@article{b784da9dd5194437bdd187685b23ef58,
title = "Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome",
abstract = "The aim of this study was to compare the effect of aliskiren and losartan on fibrinolysis and insulin sensitivity (IS) in hypertensive patients with metabolic syndrome. After 2-week placebo period, 76 outpatients with mild to moderate hypertension and metabolic syndrome were randomized to aliskiren 300mg od or losartan 100mg od for 12 weeks. Clinic blood pressure (BP), plasma PAI-1 antigen, and tPA activity were evaluated after 2, 4, 8, and 12 weeks of treatment. At the end of each treatment period patients performed an euglycemic hyperinsulinemic clamp and IS was assessed by glucose infusion rate (GIR). Both aliskiren and losartan induced a significant and similar SBP/DBP reduction (-15.6/10.7mmHg and -15.5/10.5mmHg, p",
keywords = "AT1R blockers, PAI-1 antigen, renin inhibition, tPA activity",
author = "R. Fogari and A. Zoppi and A. Mugellini and P. Lazzari and G. Derosa",
year = "2010",
doi = "10.1055/s-0030-1263123",
language = "English",
volume = "42",
pages = "892--896",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "12",

}

TY - JOUR

T1 - Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome

AU - Fogari, R.

AU - Zoppi, A.

AU - Mugellini, A.

AU - Lazzari, P.

AU - Derosa, G.

PY - 2010

Y1 - 2010

N2 - The aim of this study was to compare the effect of aliskiren and losartan on fibrinolysis and insulin sensitivity (IS) in hypertensive patients with metabolic syndrome. After 2-week placebo period, 76 outpatients with mild to moderate hypertension and metabolic syndrome were randomized to aliskiren 300mg od or losartan 100mg od for 12 weeks. Clinic blood pressure (BP), plasma PAI-1 antigen, and tPA activity were evaluated after 2, 4, 8, and 12 weeks of treatment. At the end of each treatment period patients performed an euglycemic hyperinsulinemic clamp and IS was assessed by glucose infusion rate (GIR). Both aliskiren and losartan induced a significant and similar SBP/DBP reduction (-15.6/10.7mmHg and -15.5/10.5mmHg, p

AB - The aim of this study was to compare the effect of aliskiren and losartan on fibrinolysis and insulin sensitivity (IS) in hypertensive patients with metabolic syndrome. After 2-week placebo period, 76 outpatients with mild to moderate hypertension and metabolic syndrome were randomized to aliskiren 300mg od or losartan 100mg od for 12 weeks. Clinic blood pressure (BP), plasma PAI-1 antigen, and tPA activity were evaluated after 2, 4, 8, and 12 weeks of treatment. At the end of each treatment period patients performed an euglycemic hyperinsulinemic clamp and IS was assessed by glucose infusion rate (GIR). Both aliskiren and losartan induced a significant and similar SBP/DBP reduction (-15.6/10.7mmHg and -15.5/10.5mmHg, p

KW - AT1R blockers

KW - PAI-1 antigen

KW - renin inhibition

KW - tPA activity

UR - http://www.scopus.com/inward/record.url?scp=78249240095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249240095&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1263123

DO - 10.1055/s-0030-1263123

M3 - Article

C2 - 20814848

AN - SCOPUS:78249240095

VL - 42

SP - 892

EP - 896

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 12

ER -